<DOC>
	<DOCNO>NCT02785354</DOCNO>
	<brief_summary>The study analysis use French national health insurance database , six month begin NOAC launch NVAF indication . The aim compare one-year , two-year three-year benefit-risk ( major bleeding , arterial thrombotic event , myocardial infarction ( MI ) , death ) patient start NOAC patient start VKA NVAF 2013</brief_summary>
	<brief_title>Anticoagulants Comparative Benefit-risk Ratio Real Life</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Inclusion criterion : Patients NVAF first reimburse dispensation Pradaxa® , Xarelto® , VKA 2013 , identify indication anticoagulation ; Without VKA NOAC ( Pradaxa® , Xarelto® , Eliquis® ) reimburse dispensation last 3 year first reimburse dispensation Pradaxa® , Xarelto® , VKA Exclusion criterion :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>